![R. Jacob Vogelstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
R. Jacob Vogelstein
Director/Board Member at
IAMBIC THERAPEUTICS, INC.
Profile
Dr. Rachel J.
Vogelstein is an Independent Director at Iambic Therapeutics, Inc., a Co-Founder & Managing Partner at Catalio Capital Management LP, a Co- Founder & Managing Partner at Catalio Capital Management LP, a Chief Executive Officer at Cage Pharma, Inc., an Advisor at Mind-X Corp.
and a Director & Manager at Catalio Genesis Fund II LLC.
He is on the Board of Directors at Iambic Therapeutics, Inc., Catalio Access Fund V LLC, Catalio Genesis Fund IV LLC, Catalio Special Opportunities Fund III LLC, Haystack Oncology, Inc. and Catalio Genesis Fund II LLC.
Dr. Vogelstein was previously employed as a General Partner by Camden Partners Holdings LLC, a Partner by Camden Partners Private Equity, a Partner by Global Domain Partners LLC, and an Advisor by Gigantum, Inc. He also served on the board at Aruene Corp.
and Metabolon, Inc. He received his undergraduate degree from Brown University and a doctorate degree from The Johns Hopkins University School of Medicine.
R. Jacob Vogelstein active positions
| Companies | Position | Start |
|---|---|---|
| IAMBIC THERAPEUTICS, INC. | Director/Board Member | 30/06/2021 |
Cage Pharma, Inc.
 Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical drugs | Chief Executive Officer | 30/11/2017 |
Haystack Oncology, Inc.
 Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Operates as an oncology care and MRD testing center | Director/Board Member | - |
Catalio Capital Management LP (Investment Management)
 Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio-IM aims to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management and execution. The firm’s public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy that invests in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data. The strategy’s investment style is a “best idea” orientation focused on identifying mis-priced risk in clinical, regulatory, intellectual property, manufacturing, commercial, and management. | Chief Executive Officer | 31/12/2019 |
Catalio Genesis Fund IV LLC
 Catalio Genesis Fund IV LLC Investment ManagersFinance Functions as a venture capital fund | Director/Board Member | - |
Catalio Genesis Fund II LLC
 Catalio Genesis Fund II LLC Investment ManagersFinance Functions as a venture capital fund | Director/Board Member | - |
Catalio Special Opportunities Fund Iii LLC
 Catalio Special Opportunities Fund Iii LLC Investment ManagersFinance Functions as a venture capital fund | Director/Board Member | - |
Catalio Access Fund V LLC
 Catalio Access Fund V LLC Investment ManagersFinance Functions as a venture capital fund | Director/Board Member | - |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Founder | 31/05/2020 |
| ░░░░░░ ░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Former positions of R. Jacob Vogelstein
| Companies | Position | End |
|---|---|---|
| ░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Education of R. Jacob Vogelstein
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
62
1st degree connections
18
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 18 |
|---|---|
Camden Partners Holdings LLC
 Camden Partners Holdings LLC Investment ManagersFinance Provides investment and management services | Finance |
Metabolon, Inc.
 Metabolon, Inc. Miscellaneous Commercial ServicesCommercial Services Provides metabolomics analysis and bioinformatics software solutions | Commercial Services |
Global Domain Partners LLC
 Global Domain Partners LLC Investment Banks/BrokersFinance Provides security and trading services | Finance |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Camden Partners Private Equity
 Camden Partners Private Equity Investment ManagersFinance Camden Partners invests in lower middle market companies located in the United States with an enterprise value ranging from USD 10 to 150 million and revenues of USD 10 to 50 million. The firm target companies operating in the fields of technology & software, tech & business services and education. It provides financing for buyout and growth stage transactions with an investment size ranging from USD 5 to 15 million. | Finance |
Aruene Corp.
 Aruene Corp. Medical SpecialtiesHealth Technology Develops portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treatment of migraine | Health Technology |
Cage Pharma, Inc.
Cage Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical drugs | Health Technology |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mind-X Corp.
 Mind-X Corp. Packaged SoftwareTechnology Services Develops software applications | Technology Services |
Gigantum, Inc.
 Gigantum, Inc. Packaged SoftwareTechnology Services Develops open-source platform | Technology Services |
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of life sciences developing next-generation drugs, devices and diagnostics, data, tools and innovative healthcare sectors. It provides financing for seed, early and later stage capital requirements and also makes co-investments. | Finance |
Entos, Inc.
 Entos, Inc. BiotechnologyHealth Technology Operates as a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform | Health Technology |
Catalio Access Fund V LLC
Catalio Access Fund V LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Genesis Fund II LLC
Catalio Genesis Fund II LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Genesis Fund IV LLC
Catalio Genesis Fund IV LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Catalio Special Opportunities Fund Iii LLC
Catalio Special Opportunities Fund Iii LLC Investment ManagersFinance Functions as a venture capital fund | Finance |
Haystack Oncology, Inc.
Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Operates as an oncology care and MRD testing center | Health Services |
Catalio Capital Management LP (Investment Management)
Catalio Capital Management LP (Investment Management) Investment ManagersFinance Catalio-IM aims to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management and execution. The firm’s public equities strategy is a long bias, fundamental, bottoms-up equity long/short strategy that invests in global healthcare equities across sectors: innovative drugs, devices, diagnostics and data. The strategy’s investment style is a “best idea” orientation focused on identifying mis-priced risk in clinical, regulatory, intellectual property, manufacturing, commercial, and management. | Finance |
- Stock Market
- Insiders
- R. Jacob Vogelstein
